Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Reduced serum orexin-A levels in autoimmune encephalitis and neuromyelitis optica patients.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Multiple sclerosis.
Function and distribution of three types of rectifying channel in rat spinal root myelinated axons.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome.
Visual Functional and Histopathological Correlation in Experimental Autoimmune Optic Neuritis.
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Laquinimod for multiple sclerosis.
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Molecular properties of epithelial, amiloride-blockable Na+ channels.
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.

Pages